GNPX:NASDAQGenprex, Inc. Analysis

Technical outlook is decidedly bearish: the 20‑day SMA (0.91) sits well below both the 50‑day (1.37) and 200‑day (5.06) averages, the RSI is at 26.7 indicating oversold conditions, and price ($0.805) is hovering just above the identified support level ($0.791) while volume trends downward. Despite a bullish MACD histogram, the MACD line remains negative and the beta of 2.29 signals amplified market swings, compounded by a 30‑day volatility of over 80% and a historic max drawdown of –98%.
Fundamentals are weak: Genprex reports zero revenue, negative earnings per share (‑$17.03 trailing, ‑$2.18 forward), and substantial cash burn (operating cash flow ‑$14.3 M, free cash flow ‑$9.0 M). The company carries no debt but also lacks any dividend or earnings base, resulting in a negative forward PE and a price‑to‑book of 0.33. Recent news highlights promising pre‑clinical data and a new biomarker research agreement with MD Anderson, yet these are early‑stage developments that have yet to translate into commercial traction. Investors should weigh the speculative upside of the pipeline against the severe financial and market risks.